rxstat › Classes › Drugs Affecting Bone Structure And Mineralization

Drugs Affecting Bone Structure And Mineralization: shortage status in Canada

6 of the 7 drugs affecting bone structure and mineralization rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.

Alendronic Acid Partial shortage 3 of 20 reported products affected Alendronic Acid Vitamin D3 (Fosavance) Partial shortage 2 of 8 reported products affected Etidronate Disodium Partial shortage 1 of 2 reported products affected Pamidronate Disodium Partial shortage 1 of 7 reported products affected Risedronate (Actonel) Partial shortage 3 of 23 reported products affected Zoledronic Acid (Zometa) Partial shortage 2 of 14 reported products affected Clodronate Disodium (Bonefos) Discontinued 0 of 2 reported products affected

Guides: what to do when your medication is in shortage · how to read these statuses

Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.